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Abstract
Background: Over the last decades important risk factors for gastrointestinal symptoms have shifted, which may have
changed its population prevalence. The aim of this study was to assess the current prevalence of gastrointestinal symptoms,
appraise associated factors and assess health-related quality of life in the general population.
Methods: A total of 51,869 questionnaires were sent to a representative sample of the Dutch adult general population in
December 2008. Demographic characteristics, gastrointestinal symptoms, health-related quality of life, medication use and
co-morbidity were reported. We used multivariable logistic regression analysis to determine factors associated with
gastrointestinal symptoms.
Results: A total of 18,317 questionnaires were returned, and 16,758 were eligible for analysis. Prevalence of gastrointestinal
symptoms was 26%. Most frequent symptoms were bloating (63%), borborygmi (60%) and flatulence (71%). Female gender
(adjusted OR (aOR) 1.59, 95% CI 1.43–1.77), asthma/COPD (aOR 1.47, 95% CI 1.21–1.79), use of paracetamol (aOR 1.33, 95%
CI 1.20–1.47), antidepressants (aOR 1.56, 95% CI 1.22–2.00) and acid-suppressive medication were independently associated
with presence of gastrointestinal symptoms. Age over 65 years (aOR 0.75, 95% CI 0.65–0.87), and use of statins (aOR 0.75,
95% CI 0.61–0.93) were associated with a lower prevalence of gastrointestinal symptoms. Respondents with gastrointestinal
symptoms had a lower mean health-related quality of life of 0.81 (SD= 0.21) compared to 0.92 (SD= 0.14) for persons
without gastrointestinal symptoms (P,0.01).
Conclusions: Prevalence of gastrointestinal symptoms in the Dutch community is high and associated with decreased
health-related quality of life.
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Introduction
Gastrointestinal symptoms are highly prevalent in the general
population and are a frequent cause for consultation of a general
practitioner [1]. Individuals with gastrointestinal symptoms
contribute heavily to healthcare utilization and budgeting. The
yearly costs for individual patients with gastrointestinal symptoms
are steep. For example, in the United States average direct
healthcare costs for a number of symptoms such as constipation
($7522), functional abdominal pain ($7646) and irritable bowel
syndrome ($5049) are considerable [2].
Large population studies in Western countries reported a widely
ranging prevalence of dyspepsia from 10% to more than 50%
[1,3–12]. However, these studies were performed about 20 years
ago and the risk factor profile for gastrointestinal symptoms has
shifted since. For example, the incidence of Helicobacter pylori has
rapidly decreased in the industrialized world [13,14], while use of
proton pump inhibitors (PPIs) has been on the rise [15–17].
PLOS ONE | www.plosone.org 1 July 2013 | Volume 8 | Issue 7 | e69876
Simultaneously, use of gastrotoxic medication, e.g. non-steroidal
anti-inflammatory drugs (NSAIDs) and low-dose aspirin, is high
[18]. Finally, there is a global epidemic of obesity, which is
associated with gastrointestinal symptoms and disorders, especially
gastroesophageal reflux disease (GERD) [19,20]. The overall
prevalence of upper gastrointestinal symptoms ranged from 24%
to 45% in a recent study in 13 European countries [21]. Although
performed in the current era, this study emphasized on
socioeconomic factors, and did not report associations between
gastrointestinal symptoms and modifiable factors such as BMI and
smoking on an individual level [21].
Health-related quality of life is an important parameter in
modern medicine and refers to the extent that an individual’s
physical, emotional and social well-being is affected by a medical
condition and its treatment. Individuals with gastrointestinal
symptoms report a lower health-related quality of life [22–24],
but this has been mainly studied in a subgroup of patients that
have presented to a healthcare provider, which may not be a
representative group. The exact impact of gastrointestinal
symptoms on all domains of health related quality of life in the
general –including non-healthcare visiting- population remains
unclear.
Given abovementioned considerations, new data on the
prevalence of gastrointestinal symptoms in the general population
are warranted. We hypothesize that the prevalence, despite all
changes, has remained stable. The aims of our study were to
assess: 1) the prevalence of gastrointestinal symptoms in the
general population; 2) factors associated with presence of
gastrointestinal symptoms; and 3) the effect of gastrointestinal
symptom presence on health-related quality of life.
Materials and Methods
Study Population
We sent 51,869 questionnaires by postal mail to a sample of the
Dutch population in December 2008. Invited subjects were at least
18 years and randomly selected from municipal databases of five
different municipalities. These villages and cities were selected on
their geographical location in The Netherlands, in order to fetch a
representative sample. We included returned questionnaires until
the end of March 2009. We excluded returned questionnaires with
(1) missing of all baseline variables, (2) missing of all gastrointes-
tinal symptoms, (3) missing of the primary outcome measure, or (4)
unreadable input about medication use.
The Medical Ethical Committee of the Radboud University
Nijmegen assessed the proposal of this study and concluded that it
could be waived for ethical review, as questionnaires were
returned and stored anonymously, and (non-)responders would
not be contacted again. For this reason, we did not obtain written
informed consent of all participants.
Questionnaire
The questionnaire we used was specifically designed to assess
demographic information, gastrointestinal symptoms, medication
use, healthcare visits, and health-related quality of life, and has
been used before [15,25,26]. Respondents were asked whether
they suffer from gastrointestinal symptoms in general and
subsequently for presence of 26 gastrointestinal symptoms
including nausea, early satiety, bloating, constipation and
diarrhoea. Severity of gastrointestinal symptoms was assessed on
a seven-point Likert scale (0 = absent, 1 = almost absent, 2 =mild,
3 =moderate, 4 =moderately severe, 5 = severe, 6 = very severe)
during the preceding four weeks [27]. A symptom was considered
to be present when scored $2.
Our primary outcome was the presence or absence of
gastrointestinal symptoms, which was assessed with the question:
‘‘Do you experience gastrointestinal complaints?’’ and had to be
answered with either ‘‘yes’’ or ‘‘no’’. Secondary outcomes were
type of gastrointestinal symptoms experienced in the preceding
four weeks and health-related quality of life, which was assessed
with the validated EQ-5D questionnaire [28]. The EQ-5D
comprises 5 domains of health status: mobility, self-care, usual
activities, pain/discomfort and anxiety/depression. Each domain
has 3 degrees of severity: no problems, some problems or extreme
Figure 1. Flow chart. *Some respondents fulfilled more than 1 exclusion criterion.
doi:10.1371/journal.pone.0069876.g001
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problems. The EQ-5D tariffs were calculated by using Dutch
coefficients for Time Trade Off tariffs [29]. The EQ-5D
questionnaire also contains a visual analogue scale (EQ VAS),
ranging from the worst imaginable health status to the best
imaginable health status.
We defined excessive consumption of alcohol as $14 units
(women) or$21 units (men) per week [30]. Body mass index (BMI
in kg/m2) was categorized in,25 (normal weight) and 25 or more
(overweight or obese) [31]. Excessive coffee consumption was
defined as 42 cups or more per week [25,32].
Statistical Analysis
We analysed data using Statistical Package for the Social
Sciences (SPSS), version 16.0 (IBM Corporation, New York,
United States). Frequency tables were provided for respondents’
characteristics and for secondary outcomes. Pearson’s chi squared
(x2) analysis was used to compare categorical variables between
respondents with and without presence of gastrointestinal symp-
toms. Continuous variables were compared between the two
groups using Student’s T-test or Mann-Whitney U method
whenever appropriate. We calculated presence of various symp-
toms at various ages by calculating symptom presence per 10
years. Univariable and multivariable logistic regression analysis
were performed to identify factors associated with gastrointestinal
symptoms. Odds ratios and 95% confidence intervals were stated.
Covariates were included in multivariable regression analysis
based on a predefined conceptual model that was based on
published literature. We also included covariates if they were
univariably associated with the primary outcome (p,0.01).
Health-related quality of life was compared between respon-
dents with and without gastrointestinal symptoms. The 5 domains
of the EQ-5D questionnaire were compared using chi squared (x2)
analysis. Dutch utility scores for every individual symptom in
persons reporting gastrointestinal symptoms were calculated to
assess the impact of an individual symptom on health-related
quality of life. Correlation between gastrointestinal symptom score
Table 1. Population characteristics and factors associated with gastrointestinal symptom presence.
Respondents with
gastrointestinal
symptoms
Respondents without
gastrointestinal
symptoms Unadjusted OR (95% CI) Adjusted OR (95% CI)
n/N n/N
Mean age (6SD) 48.9 (16) 50.2 (16) – –
$65 years (%) 747/4,300 (17) 2,451/12,389 (20) 0.85 (0.78–0.93) 0.75 (0.65–0.87)
Female (%) 2,784/4,217 (66) 6,448/12,079 (53) 1.70 (1.58–1.83) 1.59 (1.43–1.77)
Body mass index $25 kg/m2 (%) 2,067/4,224 (49) 5,549/12,213 (45) 1.15 (1.07–1.23) 1.02 (0.92–1.13)
Smoking (%) 840/4,247 (20) 2,089/12,242 (17) 1.20 (1.10–1.31) 1.12 (0.98–1.27)
Excessive alcohol consumption* (%) 394/2,919 (14) 1,229/9,266 (13) 1.02 (0.90–1.15) 0.93 (0.81–1.07)
Excessive coffee consumption{ (%) 352/3,612 (10) 1,241/10,828 (12) 0.83 (0.74–0.95) 0.87 (0.74–1.02)
Co-morbidity (%)
Diabetes mellitus 238/4,315 (6) 639/12,443 (5) 1.08 (0.93–1.26) 0.85 (0.64–1.13)
Rheumatoid arthritis 316/4,315 (7) 457/12,443 (4) 2.07 (1.79–2.40) 1.27 (0.99–1.62)
Asthma/COPD 393/4,315 (9) 651/12,443 (5) 1.82 (1.59–2.07) 1.47 (1.21–1.79)
Medication use
PPIs1 1,161/4,315 (27) 610/12,443 (5) 7.14 (6.43–7.94) 9.28 (7.91–10.9)
H2RAs** 212/4,315 (5) 75/12,443 (1) 8.52 (6.53–11.1) 9.93 (6.72–14.7)
Antacids 588/4,315 (14) 437/12,443 (4) 4.33 (3.81–4.93) 4.22 (3.53–5.05)
Paracetamol 2,529/4,315 (59) 5,763/12,443 (46) 1.64 (1.53–1.76) 1.33 (1.20–1.47)
NSAIDs" 1,076/4,315 (25) 2,157/12,443 (17) 1.58 (1.46–1.72) 1.02 (0.90–1.15)
Antiplatelet therapy# 462/4,315 (11) 1,221/12,443 (10) 1.10 (0.98–1.23) 1.08 (0.89–1.30)
Antidepressants 278/4,315 (6) 423/12,443 (3) 1.96 (1.68–2.29) 1.56 (1.22–2.00)
Statins 435/4,315 (10) 1,285/12,443 (10) 0.97 (0.87–1.09) 0.75 (0.61–0.93)
Oral contraceptives 339/4,315 (8) 716/12,443 (6) 1.40 (1.22–1.60) 1.22 (0.99–1.51)
Beta blockers 487/4,315 (11) 1,286/12,443 10) 1.10 (0.99–1.23) 0.87 (0.71–1.06)
ACE-inhibitors 227/4,315 (5) 727/12,443 (6) 0.90 (0.77–1.04) 0.81 (0.62–1.06)
Angiotensin-receptor antagonist 186/4,315 (4) 517/12,443 (4) 1.04 (0.88–1.23) 0.77 (0.58–1.03)
Diuretics 390/4,315 (9) 1,052/12,443 (9) 1.08 (0.95–1.22) 0.85 (0.68–1.06)
N/D =not determined.
*Excessive alcohol consumption is 14 units or more a week for women and 21 units or more a week for men.
{Excessive coffee consumption was defined as 42 cups a week and more.
1PPI: proton pump inhibitor.
**H2RA: histamine-2 receptor antagonist.
"NSAIDs: non-steroidal anti-inflammatory drugs.
#Antiplatelet therapy: low-dose acetylsalicylic acid, carbasalate calcium, clopidogrel and dipyridamol are taken together.
doi:10.1371/journal.pone.0069876.t001
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(VAS) and health-related quality of life (EQ VAS) was calculated
with a Spearman correlation. A p-value,0.01 was assumed to be
statistically significant.
Results
A total of 18,317 (35%) questionnaires were returned, of which
742 returned unopened and uncompleted. After applying our
predetermined exclusion criteria, a total of 16,758 questionnaires
were included in our analyses (Figure 1). In total, 4,315 persons
(26%) reported gastrointestinal symptoms, with a median symp-
tom duration of 8 years (interquartile range 3–18 years).
Compared to participants not reporting symptoms, those with
gastrointestinal symptoms were younger (48.9616 vs. 50.2616
years), more often female (66% vs. 53%), and reported more
frequently use of any medication (overall 80% vs 67%; Table 1).
The most frequently reported upper gastrointestinal symptoms
were bloating (63%) and belching (45%; Table 2). Flatulence
(71%) and borborygmi (60%) were the most frequently reported
lower gastrointestinal tract symptoms (Table 3). Distribution of
symptom presence among different age categories is depicted in
Table 4.
The overall prevalence of gastrointestinal symptoms decreased
with ageing. This was apparent in females (P,0.01), but not in
males (P = 0.22; Table S1). There was no effect of Body Mass
Index on upper versus lower gastrointestinal symptoms (data not
shown).
Factors Associated with Gastrointestinal Symptoms
We found that respondents with gastrointestinal symptoms
more frequently reported acid suppressive medication use. Other
factors that were also more frequently reported in respondents
with gastrointestinal symptoms are depicted in Table 1.
After adjustment, female gender (adjusted OR (aOR) 1.59, 95%
CI 1.43–1.77), asthma/COPD (aOR 1.47, 95% CI 1.21–1.79),
use of paracetamol (aOR 1.33, 95% CI 1.20–1.47), antidepres-
sants (aOR 1.56, 95% CI 1.22–2.00) and use of acid-suppressive
medication (antacids aOR 4.22, 95% CI 3.53–5.05, H2RAs aOR
9.93, 95% CI 6.72–14.7, PPIs aOR 9.29, 95% CI 7.91–10.9)
remained independently associated with a higher risk for presence
of gastrointestinal symptoms (Table 1). Age $65 years (aOR
0.75, 95% CI 0.65–0.87), and use of statins (aOR 0.75, 95% CI
0.61–0.93) were independently associated with a lower risk for
presence of gastrointestinal symptoms. In the univariable analysis
obesity was associated with presence of gastrointestinal symptoms
(OR 1.15, 95% CI 1.10–1.31), but this association was lost after
adjustment (aOR 1.02, 95% CI 0.92–1.13).
Health-related Quality of Life
The mean utility for health-related quality of life was statistically
significantly lower for respondents with gastrointestinal symptoms
(0.81, SD 0.21) compared to respondents without gastrointestinal
symptoms (0.92, SD 0.14, p,0.01). This difference was statistically
significant (p,0.01) for all dimensions, and most pronounced for
dimensions ‘‘pain/discomfort’’, ‘‘anxiety/depression’’, and ‘‘usual
activities’’ (Table 5). The gastrointestinal symptom score (VAS)
correlated negatively with health-related quality of life (EQ VAS)
with a Spearman correlation of 20.57 (p,0.01), indicating that
persons with more severe gastrointestinal symptoms reported a
lower health-related quality of life. The following individual
symptoms were associated with the lowest health-related quality of
life: haematemesis (0.54, SD 0.32), dysphagia for liquid (0.59, SD
Table 2. Type and frequency of upper gastrointestinal
symptoms in respondents experiencing gastrointestinal
symptoms.
Number of respondents, n/N (%)
Epigastric pain
In general 1,407/3,842 (36.6)
During daytime 1,422/3,565 (39.9)
At night 867/3,452 (25.1)
Heartburn
In general 1,366/3,916 (34.9)
During daytime 1,250/3,537 (35.3)
At night 953/3,494 (27.3)
Regurgitation 1,545/4,012 (38.5)
Belching 1,884/4,166 (45.2)
Empty feeling 1,008/4,039 (25.0)
Bloating 2,627/4,164 (63.1)
Nausea 1,278/4,139 (30.9)
Vomiting 327/4,109 (8.0)
Loss of appetite 796/4,119 (19.3)
Early satiety 1,409/4,121 (34.2)
Haematemesis 36/4,091 (0.9)
Dysphagia
For liquids 141/4,088 (3.4)
For solid food 257/3,957 (6.5)
doi:10.1371/journal.pone.0069876.t002
Table 3. Type and frequency of lower gastrointestinal
symptoms in respondents experiencing gastrointestinal
symptoms.
Number of respondents,
n/N (%)
Lower abdominal pain
In general 1,755/4,075 (43.1)
Postprandial 1,176/3,477 (33.8)
Pre-prandial 726/3,379 (21.5)
No reduction after defecation 867/3,338 (26.0)
Flatulence 2,965/4,193 (70.7)
Borborygmi 2,479/4,138 (59.9)
Abnormal defecation
Black stools 338/3,714 (9.1)
Blood 187/3,708 (5.0)
Mucous 557/3,751 (14.8)
Frequently hard 1,418/3,810 (37.2)
Diarrhoea 1,330/3,812 (34.9)
Constipation 1,060/3,859 (27.5)
Alternately solid or loose 1,939/3,979 (48.7)
Frequently painful 908/3,818 (23.8)
Strong urgency 1,541/3,853 (40.0)
Incomplete 1,143/3,811 (30.0)
Fatty stools 1,012/3,882 (26.1)
doi:10.1371/journal.pone.0069876.t003
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0.32) and solid intake (0.62, SD 0.30) and vomiting (0.66, SD 0.30;
Table S2).
Discussion
We found that 26% of the general population reported
gastrointestinal symptoms, with a median duration of eight years.
Our study identifies female gender, asthma/COPD, use of
paracetamol, antidepressants and acid suppressive medication
use as risk factors that were independently associated with a higher
prevalence of gastrointestinal symptoms. Older age and statin use
protected against gastrointestinal symptoms. Respondents with
gastrointestinal symptoms had an impaired health-related quality
of life. In comparison to other, older, studies in the field [1,3–12],
we found a similar prevalence of gastrointestinal symptoms in the
community. This suggests that the effect of time is limited,
although there are a plethora of differences between our study and
others, most importantly the definitions used to assess prevalence
of gastrointestinal symptoms.
We found that females more frequently reported gastrointestinal
symptoms, which is in line with other studies regarding
gastrointestinal symptoms [9,25,33]. In our study, presence of
asthma or COPD was an independent risk factor. Presence of
asthma is associated with GERD, [34,35], and recent studies
indicate an increased prevalence of GERD symptoms in patients
with COPD [36–38]. Medication use, and especially paracetamol,
antidepressants, and acid-suppressive medication contributed
Table 4. Symptom presence in respondents with gastrointestinal symptoms at various age categories.
Age categories
18–30 years 31–40 years 41–50 years 51–60 years 61–70 years $71 years
n/N (%) n/N (%) n/N (%) n/N (%) n/N (%) n/N (%)
Epigastric pain in general 257/650 (39.5) 238/627 (38.0) 303/799 (37.9) 323/856 (37.7) 196/594 (33.0) 88/305 (28.9)
Belching 335/672 (49.9) 288/651 (44.2) 396/870 (45.5) 428/932 (45.9) 278/678 (41.0) 153/349 (43.8)
Bloating 486/667 (72.9) 441/647 (68.2) 579/865 (66.9) 583/942 (61.9) 351/678 (51.8) 181/352 (51.4)
Heartburn in general 184/666 (27.6) 223/636 (35.1) 321/822 (39.1) 324/853 (38.0) 200/614 (32.6) 108/314 (34.4)
Borborygmi 511/669 (76.4) 411/644 (63.8) 523/864 (60.5) 518/930 (55.7) 331/669 (49.5) 179/350 (51.1)
Constipation 237/654 (36.2) 194/618 (31.4) 224/808 (27.7) 203/851 (23.9) 111/604 (18.4) 86/311 (27.7)
doi:10.1371/journal.pone.0069876.t004
Table 5. Health-related quality of life in respondents with and without gastrointestinal symptoms.
Respondents with gastrointestinal
symptoms
Respondents without gastrointestinal
symptoms
EQ-5D dimension n/N (%) n/N (%) P-value
Mobility ,0.001
No problems 3,440/4,203 (81.8) 10,880/12,194 (89.2)
Some problems 745/4,203 (17.7) 1,290/12,194 (10.6)
Extreme problems 18/4,203 (0.4) 24/12,194 (0.2)
Self-care ,0.001
No problems 4,039/4,191 (96.4) 11,904/12,154 (97.9)
Some problems 134/4,191 (3.2) 219/12,154 (1.8)
Extreme problems 18/4,191 (0.4) 31/12,154 (0.3)
Usual activities ,0.001
No problems 3,179/4,213 (75.5) 11,029/12,173 (90.6)
Some problems 952/4,213 (22.6) 1,065/12,173 (8.7)
Extreme problems 82//4,213 (1.9) 79/12,173 (0.6)
Pain/discomfort ,0.001
No problems 1,715/4,209 (40.7) 9,424/12,128 (77.7)
Some problems 2,263/4,209 (53.8) 2,559/12,128 (21.1)
Extreme problems 231/4,209 (5.5) 145/12,128 (1.2)
Anxiety/depression ,0.001
No problems 2,893/4,215 (68.6) 10,559/12,131 (87.0)
Some problems 1,185/4,215 (28.1) 1,485/12,131 (12.2)
Extreme problems 137/4,215 (3.3) 87/12,131 (0.7)
doi:10.1371/journal.pone.0069876.t005
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significantly to presence of gastrointestinal symptoms in our large
population-based survey. The independent association found for
paracetamol, probably stems from the use of paracetamol as a
panacea for gastrointestinal symptoms. We surmise that this
hypothesis also applies to the relation between acid-suppressive
medication and gastrointestinal symptoms. The association
between antidepressants and gastrointestinal symptoms is complex
due to the interactions between: 1) depression and gastrointestinal
symptoms; 2) depression and antidepressant use, and 3) antide-
pressant use and gastrointestinal symptoms [39–48].
A total of 11% of our studied population reported PPI use, 2%
H2RA use and 6% antacid use. This is much lower than the use of
so-called ‘indigestion remedies’ in a study by Jones et al. prior to
the PPI era, in which 47–55% of respondents reported any use of
this medication class [3]. Use of PPIs was strongly associated with
gastrointestinal symptom presence in our study (adjusted OR 9.28,
95% CI 7.91–10.9). This can by explained by a combination of
indication bias, partial responsiveness on PPI therapy and
assessment of both upper and lower gastrointestinal symptom
presence. However, the prevalence of gastrointestinal symptoms
would be even higher if we would include respondents with acid
suppressive medication without current gastrointestinal symptoms
in our prevalence.
In a recently published study, the prevalence of upper
gastrointestinal symptoms in The Netherlands, the country where
our study was performed, was 24% [21]. We found an almost
similar prevalence (26%), but we assessed both upper and lower
gastrointestinal symptoms. We found that the majority of
respondents with gastrointestinal symptoms had both upper and
lower gastrointestinal symptoms. Respondents with upper gastro-
intestinal symptoms have a higher risk for associated lower
gastrointestinal symptoms. This is in line with a Japanese study
that reported overlap of GERD, functional dyspepsia and IBS in
45% of their studied population [23]. Moreover, in the natural
history of functional gastrointestinal disorders many patients
frequently switch between upper and lower gastrointestinal
symptoms [49].
We also reported the impact of gastrointestinal symptoms on
health-related quality of life. Gastrointestinal symptoms were
associated with a disutility of 0.11, which was in line with a
disutility for dyspeptic symptoms of 0.09 in another study [50].
Furthermore, we observed that more severe symptoms correlated
with a lower health-related quality of life (Table S2). By
presenting a wide variety of utilities, we have delivered input for
cost-utility studies. These studies become more and more
important, and are incorporated in clinical guidelines, e.g. by
the National Institute for Health and Care and Excellence (NICE).
The major strength of our study is that we examined commonly
experienced symptoms in the community by use of a broad
definition. Secondly, in order to attain a representative sample,
persons were randomly selected via databases of local authorities
without stringent in- and exclusion criteria. Third, we studied
gastrointestinal symptoms overall and per symptom instead of in
clusters of gastrointestinal symptoms.
Our study design comes with limitations. We cannot exclude
response bias, as our response rate was 35%. Response rates in
epidemiological studies are declining the last decades and this
problem is faced by multiple researchers [51,52]. A study by Galea
et al. describes that a low response rate is not inevitably leading to
substantial changes in outcomes [51]. Since our study was
performed with postal questionnaires, in comparison to digital
surveys, our response rate is actually not that low and still within
the range of an acceptable response rate according to Galea et al.
Due to concealment we were not able to perform non-responder
research. We tried to minimize this bias by inviting all subjects
with a personalized cover letter, and we asked explicitly to return
the questionnaire, irrespective of presence of gastrointestinal
symptoms. Seventy-four percent of all responders did not report
the presence of gastrointestinal symptoms. Furthermore, the
prevalence of co-morbidities in our study cohort resembles the
prevalence in the general population [53]. Therefore, we assume
that response bias might be limited. We also cannot exclude that
bias was introduced by exclusion of individuals with incomplete
information about gastrointestinal symptoms.
The results of our study will refresh awareness among
healthcare providers on the high prevalence of gastrointestinal
symptoms in the general population. Future research should focus
on new targets to effectively treat patients with gastrointestinal
symptoms, as we have shown that even many users of acid
suppressive medication still report presence of symptoms.
In conclusion, despite increased treatment options and alter-
ations in risk factors, the prevalence of gastrointestinal symptoms
in the western community remains high and is associated with a
considerable decrease in health-related quality of life.
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